Omega Funds — Full Portfolio

Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.

BiotechNew York, US

AMAndreas Muehler(Executive Officer)inDVDaniel Vitt(Executive Officer, Director)inINDERPAL SINGH(Executive Officer)inHella Kohlhof(Executive Officer)inPatrick Walsh(Executive Officer)Aron Stern(Executive Officer)

Board seatVOVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022

Co-investorsBABayern KapitalBMbmp VenturesFUFund+POPontifax Venture Capital

Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.

BiotechHealthtechNew York, US

DHDavid Hung(Founder)inDHDavid Hung, M.D.(Executive Officer, Director)inDavid Hanley(Chief Technical Operations Officer)inGHGary Hattersley(Chief Scientific Officer)inSMStacy Markel(Chief People Officer)inPSPhilippe Sauvage(Chief Financial Officer)in

Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020

Co-investorsAIAisling CapitalDEDecheng CapitalECEcoR1 CapitalVEVertex Ventures China

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

MDMary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)ACAdam Craig(Executive Officer, Director)in

Board seatCNClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017

Co-investorsBABain Capital Life SciencesLULumira VenturesNENew Enterprise Associates (NEA)PAPartners ResoluteTHThynk CapitalADAdvent Life Sciences+1 more

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHGHalley Gilbert(Executive Officer)RDRebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsGVGV (Google Ventures)FIFidelity InvestmentsFOForesite CapitalMIMithril Capital ManagementOROrbiMedPOPolaris Partners+3 more

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDRDavid Raben(Chief Medical Officer)in

Co-investorsAIAisling CapitalEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalPRPremji InvestRARA Capital+5 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)PIPivotal Life Sciences+3 more

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

JSJavier Szwarcberg(Executive Officer, Director)inSGSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in

BoardSimpson Camilla(Director)TATiba Aynechi(Director)in

Co-investorsAIAisling CapitalHEHealthCapRIRiverVest Venture PartnersABAbingworthNONorwest Venture PartnersNONovo Holdings+1 more

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.

BiotechHealthtechNew Haven, US

Thomas Sciascia(Executive Officer)JGJennifer Good(Co-Founder, President and CEO)inTSThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)LDLisa Delfini(Executive Officer)inWFWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in

Co-investorsAPAPERTURE Venture PartnersFRFrazier Life SciencesNENew Enterprise Associates (NEA)PIPivotal Life Sciences

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)inAAAllison Ambrose(General Counsel)inADAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)AHAdam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsOROrbiMedACAccess IndustriesACAccess BiotechnologyBABain Capital Life SciencesDEDecheng CapitalHBHBM Healthcare Investments+4 more

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

AFAdam Friedman(Chief Executive Officer)inAFAndrew Fedder(Executive Officer, Director)inBPBrian Piper(Executive Officer, Director)in

Co-investorsATAtlas VentureLILightspeed Venture PartnersVIVida VenturesTETenmileABAbingworthALAlleyCorp+1 more

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.

BiotechMedical DevicesSeattle, US

PIPiers Ingram(President, Co-Founder)inJBJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)

Co-investorsNONovo HoldingsFRFrazier Life SciencesJEJeito CapitalNONorwest Venture Partners

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

RKRaj Kannan(Executive Officer, Director)

BoardIGIvan Gergel(Director)inJVJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026

Co-investorsANAndera PartnersAVAvego BioScience CapitalGLGlobal BioAccess FundJEJeito CapitalNENew Rhein Healthcare Investors, LLCSESeroba Life Sciences+2 more

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

South San Francisco, US

Board seatOtello Stampacchia· per SEC Form D

Co-investorsBABain Capital Life SciencesFRFrazier Life SciencesLOLongitude CapitalBLBlackRockCACasdin CapitalFRFranklin Templeton+5 more

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFRFrazier Life SciencesNENextech InvestVIVida Ventures+3 more

Spiro Medical is a clinical-stage medical device company developing neuromodulation therapies for severe, uncontrolled asthma and other respiratory conditions.

BiotechHealthtechMedical DevicesBelleair Bluffs, US

Rinda Sama(Executive Officer)in

BoardBrian Mooney(Director)

Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026

Co-investorsANAndera PartnersSUSupernova Invest

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)

BoardAGArjun Goyal(Director)in

Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D

Co-investorsANAndreessen HorowitzVIVida VenturesABabrdn plcBIBiotechnology Value FundFOForesite CapitalHIHillhouse Investment+1 more

XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.

Deep TechDigital HealthHealthtechMedical DevicesUnion City, US

Garrett Schwab(Chief Executive Officer)inSKShane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)

BoardDRDuke Rohlen(Director)inJD Friedland(Director)

Board seatSaoussen Ben Halima· per SEC Form D

Co-investorsAPAPERTURE Venture PartnersBRBroadview VenturesCICincyTechINIntuitive VenturesJOJobsOhio VenturesAJAjax Health

Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).

BiotechHealthtechMedical DevicesAustin, US

Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)

BoardGPGeoff Pardo(Director)in

Co-investorsBRBroadview VenturesRIRiverVest Venture PartnersTMTMC Venture FundCACadence Healthcare VenturesGIGilde HealthcareGIGilmartin Capital LLC+2 more

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

RLRoy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)ADAmra Demirovic(Chief Human Resources Officer)NHNicole Hadas(Chief Legal Officer)

Co-investorsB B Capital GroupB4B4 CapitalF-F-Prime CapitalSOSofinnova VenturesALAlexandriaB B Capital+2 more

Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

MGMohamed Genead(Executive Officer, Director)inMTMichael Tolentino(Executive Officer, Director)inMAMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inTHTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in

Co-investorsJEJeito CapitalLOLongitude CapitalCACatalio Capital Management, LPOROrbiMedAVAvoro Capital AdvisorsDIDigitalis Ventures

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.

BiotechDigital HealthHealthtechMedical DevicesNew York, US

DBDavid B. Klein(Founder and CEO)inDKDavid Klein(Executive Officer, Director)inRSRandall Stanicky(Executive Officer)in

BoardAlex Zisson(Director)LSLee Shapiro(Director)inCDCris De Luca(Director)in

Co-investorsACAccelmed PartnersH.H.I.G. CapitalH.H.I.G. HealthBridge PartnersHEHealth Catalyst CapitalHIHikma VenturesRERevelation Partners+5 more

Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.

BiotechSan Diego, US

JHJohn Hood(Co-Founder, Chief Executive Officer & Executive Chairman)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)MMMonal Mehta(Director)inMDMiguel de los Rios(Co-Founder & Chief Scientific Officer)in

Co-investorsFIFidelity InvestmentsLOLongitude Capital

Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development.

BiotechDeep TechMedical DevicesNiel, BE

Co-investorsFUFund+PMPMVBOBoehringer Ingelheim Venture FundEQEQT Life SciencesNONovalis LifeSciencesPWPWV

Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.

BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US

CLChristine Lemke(Executive Officer, Director)inDKDeborah Kilpatrick(Executive Officer, Director)LOLeslie Oley Wilberforcein

BoardDavid Fleshman(Director)RCRowan Chapman(Director)in

Co-investorsASAsset Management CompanyB B Capital GroupB4B4 CapitalCRCross Creek AdvisorsDEDementia Discovery FundFRFresco Capital+6 more

EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.

BiotechHealthtechHolborn, London

David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)

Co-investorsJEJeito CapitalSASamsara BioCapitalSVSV Health Investors

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.

BiotechDeep TechHealthtechBasel, CH

TBTarig Bashir(Chief Executive Officer (CEO))inJWJens Würthner(Chief Medical Officer (CMO))FZFrank Zenke(Chief Scientific Officer (CSO))in

Co-investorsM M VenturesNONovartis Venture FundPFPfizer Venture Investments

GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.

Advanced ManufacturingAI & Machine LearningDeep TechHardwareWaltham, US

Micah K Johnson(Executive Officer, Director)Edward Adelson(Director)Kimo Johnson(Co-Founder & Chief Science Officer)inJanos Rohaly(Co-Founder & Chief Technology Officer)inWilliam J. Yost(Executive Officer, Director)YBYoussef Benmokhtar(Chief Executive Officer)

Co-investorsANAnzu PartnersSCScout VenturesSCScout Ventures

Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)NENextech InvestVIVida VenturesBLBlackRockCOCommodore Capital+2 more

Lysosomal Therapeutics Inc.

BiotechCambridge, US

Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)

BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)

Co-investorsSASanofi VenturesATAtlas VentureHAHatteras Venture PartnersLILilly VenturesRORoche Venture Fund

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

LGLuke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)DLDavid Liu, PhD(Founder)ALAngelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)JWJonathan Weissman, PhD

Co-investorsATAtlas VentureNENewpath Partners5A5AM VenturesARARCH Venture PartnersDCDCVC (Data Collective)F-F-Prime Capital+11 more

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

NMNeil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inCSClaus Sundgreen(Chief Medical Officer)inPTPaul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCRCriteria Bio VenturesNONovartis Venture FundSVSV Health InvestorsBRBritish Business BankM M VenturesDEDementia Discovery Fund

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

PRPablo Rojas(Founder)in

Co-investorsNONovartis Venture FundY Y CombinatorFOForbionGLGlilot Capital PartnersGLGlobal Founders CapitalHAHarvard Management Company+5 more

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

RMRichard Mulligan(Director)inHBHans Bishop(Director)SHSteve Harr(President and Chief Executive Officer)JJJames J. MacDonald(Executive Officer)NHNathan Hardy(Executive Officer)

BoardGVGeoffrey von Maltzahn(Director)in

Co-investorsAMAmerican Family VenturesARARCH Venture PartnersF-F-Prime CapitalFLFlagship PioneeringGVGV (Google Ventures)INInnovating Capital+7 more

BiotechCambridge, US

William C. Shakespeare(Director)in

BoardIDIain Dukes(Executive Officer, Director)inMRMichael Rome(Director)inCGCarl Gordon(Director)in

Co-investorsFOForesite CapitalLOLongitude CapitalNENextech InvestNENexTech VenturesOROrbiMedPOPontifax Venture Capital+2 more

Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.

BiotechDeep TechHealthtechLongevityChicago, US

Rand Sutherland(Director)inJames Sullivan(Executive Officer, Director)inJSJim Sullivan(CEO)inKHKevin Hunt(CSO)in

BoardJSJonathan Silverstein(Director)inBernard Davitian(Director)

Co-investorsAVAvoro Capital AdvisorsOROrbiMedOUOUP (Osage University Partners)POPontifax Venture CapitalAVAvoro VenturesCACasdin Capital+1 more